Participating Companies

An epi­ge­net­ic fo­cused com­pany de­vel­op­ing small molecule drugs for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany’s lead com­pound, Res­mi­no­s­tat, is fo­cused on Cu­ta­neous T Cell Lym­pho­ma but has un­part­nered as­sets for Hod­kins Lym­pho­na, Col­orec­tal Can­cer, and HCC. [more in­for­ma­tion]
Ability Pharmaceuticals, SL
ABTL0812 has been grant­ed Or­phan Drug Desig­na­tion (ODD) for neu­roblas­to­ma, pan­cre­at­ic can­cer and for biliary tract can­cer by FDA and EMA, and the drug has a sales po­ten­tial over &eu­ro;2.5 bil­lion in 2025, with a mar­ket share over 80% in se­lect­ed can­cer types. [more in­for­ma­tion]
Abliva Ab [ABLI-SE]
Fo­cused on rare and se­vere pri­mary mi­to­chon­drial dis­eas­es (PMD). KL1333, a NAD+ reg­u­la­tor, to ac­cel­er­ate in­to piv­o­tal studies in 2H21 based on pos­i­tive FDA feed­back; ini­tial re­sults from Ph1b in PMD pa­tients exp. in 1Q21. NV354, an en­er­gy re­place­ment ther­a­py for Leigh Syn­drome, in IND-en­abling studies. [more in­for­ma­tion]
Adrenomed AG
Pre­ci­sion medicine, car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; fi­nal da­ta re­leased late Novem­ber: Ear­ly ap­pli­ca­tion of Adre­cizumab leads to a rapid and sta­tis­ti­cal­ly sig­ni­f­i­cant im­prove­ment of fluid bal­ance, sys­temic or­gan func­tion and > 50% rel­a­tive re­duc­tion of all cause mor­tal­i­ty af­ter 28 days and 90 days com­pared to place­bo on top of SoC. [more in­for­ma­tion]
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. Lead can­di­date is an IL-17 with pos­i­tive Ph2 52wk da­ta in pso­ri­a­sis and Ph2 IND for lead in­di­ca­tion uvei­tis will be filed in Q1 2021. In ad­di­tion, the com­pany has an on­go­ing re­la­tion­ship with In­ma­gene in Chi­na. Backed by In­ves­tor AB. [more in­for­ma­tion]
Alligator Bioscience [ATORX:ST] SKr442 MM MCap
Al­li­ga­tor spe­cial­izes in the de­vel­op­ment of tu­mor-di­rect­ed im­munother­a­pies, in par­tic­u­lar ag­on­is­tic mono- and bis­pe­cif­ic anti­bodies. In im­munother­a­py, the pa­tients´ im­mune sys­tem is ac­ti­vat­ed to cure can­cer. The term tu­mor-di­rect­ed means that the drug is ad­min­is­tered or de­signed such that the phar­ma­co­log­i­cal ef­fect is lo­cal­ized to the tu­mor. [more in­for­ma­tion]
AM-Pharma B.V.
Re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ed Ph 3 in Q4 2020; TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts exp YE2021. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023. [more in­for­ma­tion]
Bachem Holding AG
Bachem is a lead­ing and in­no­va­tion-driv­en com­pany spe­cial­iz­ing in the de­vel­op­ment and man­u­fac­ture of pep­tides and oli­gonu­cleotides. Head­quar­tered in Switz­er­land and with lo­ca­tions in Eu­rope, the USA and Asia, Bachem op­er­ates in­ter­na­tio­n­al­ly and has 50 years of ex­pe­ri­ence and ex­per­tise that is unique in the in­dus­try. [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr2,779 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Cantargia AB [CANTA:ST] SKr5,320 MM MCap
The ba­sis for this is the pro­tein IL1RAP that is in­volved in a num­ber of dis­eas­es and where Can­tar­gia has estab­lished a plat­form. Can­tar­gia's other pro­ject, CAN10, is in the pre­clin­i­cal phase and is aim­ing to de­vel­op an IL1RAP bind­ing anti­body block­ing IL-1, IL-33 and IL-36 - op­ti­mised for the treat­ment of sys­temic scle­ro­sis and my­o­cardi­tis. [more in­for­ma­tion]
Cellestia Biotech AG
The com­pany's drugs of­fer a mode of ac­tion for the treat­ment of NOTCH de­pen­dent leukemias, lym­pho­mas and solid tu­mors through oral med­i­ca­tion, en­abling pa­tients to get ef­fi­cient treat­ment and en­sure a fast re­cov­ery. Celles­tia is com­plet­ing a Phase l first-in-man clin­i­cal trial with CB-103 treat­ing can­cer pa­tients in the EU. [more in­for­ma­tion]
COSMO Pharmaceuticals N.V. [C43.F]
Cos­mo is a spe­cial­ty phar­ma­ceu­ti­cal com­pany fo­cused in treat­ing se­lect­ed Gas­troin­testi­nal Di­s­or­ders. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]
Ellipses Pharma
El­lips­es Phar­ma is an in­ter­na­tio­n­al drug de­vel­op­ment com­pany, fo­cused ex­clu­sive­ly on the ad­vance­ment of in­no­va­tive can­cer treat­ments through the clin­ic. [more in­for­ma­tion]
En­terome is lev­er­ag­ing this ex­per­tise to de­vel­op a pipe­line of clin­i­cal and pre-clin­i­cal can­di­dates (small molecules, pro­teins and pep­tides) with a fo­cus on can­cer, au­toim­mune, in­flam­ma­to­ry and metabolic dis­eas­es. [more in­for­ma­tion]
eTheRNA immunotherapies
eTh­eR­NA was estab­lished in Jan­uary 2013 as a spin-off com­pany of the ‘Vri­je Uni­ver­siteit Brus­sel’ (VUB), fol­low­ing the de­vel­op­ment of the TriM­ix tech­nol­o­gy by the VUB Lab­o­ra­to­ry for Molec­u­lar and Cel­lu­lar Ther­a­py. It is de­vel­op­ing mR­NA based can­cer im­munother­a­pies from its unique TriM­ix plat­form. Both are be­ing de­vel­oped out­side the US. [more in­for­ma­tion]
Ethris GmbH
We are rapid­ly ap­proach­ing in vi­vo proof of con­cept for gen­er­at­ing ther­a­peu­tic anti­bodies against COVID-19 in the lung through a part­nered pro­gram while ad­vanc­ing our pipe­line of im­muno-mo­d­u­la­tion and mR­NA-based pro­tein re­place­ment ther­a­pies with the ul­ti­mate goal of im­prov­ing pa­tients’ lives [more in­for­ma­tion]
Evotec AG [EVTA:FF] US$5,150 MM MCap
The EVT In­no­vate seg­ment is an in­ter­nal drug dis­cov­ery plat­form with over 70 prod­uct op­por­tu­ni­ties and ex­per­tise across dis­eas­es ar­eas. [more in­for­ma­tion]
Ex­s­ci­en­tia is ap­p­ly­ing AI and big da­ta pro­cess­ing to ac­cel­er­ate drug dis­cov­ery and de­vel­op­ment. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €252 MM MCap
Hei­del­berg Phar­ma AG (HPHA, Frank­furt Stock Exchange), based in La­den­burg, Ger­many, is a lead­ing biotech com­pany pi­oneer­ing the use of its AT­AC (Anti­body Tar­get­ed Amanitin Con­ju­gate) plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion ef­fec­tive at spe­cif­i­cal­ly killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. [more in­for­ma­tion]
He­paRe­geniX is de­vel­op­ing nov­el ther­a­pies for the treat­ment of acute and chron­ic liv­er dis­eas­es. Since its start in 2017, He­paRe­geniX has suc­cess­ful­ly dis­cov­ered and de­vel­oped sev­er­al pre­clin­i­cal drug can­di­dates for the treat­ment of acute and chron­ic liv­er dis­eas­es based on a nov­el pro­pri­e­tary molec­u­lar tar­get Mi­to­gen-Ac­ti­vat­ed Pro­tein (MAP) Ki­nase Ki­nase 4 (MKK4). [more in­for­ma­tion]
The com­pany's lead can­di­date is HO­RA-PDE6B, which is in Phase I/II clin­i­cal trials with an in­di­ca­tion in PDE6B re­tini­tis pig­men­tosa. The se­cond prod­uct will en­ter in the clin­ic in H1 2019 The com­pany raised EUR 22.5 mil­lion of Se­ries B ven­ture fund­ing from Kur­ma Part­n­ers, Pon­ti­fax Ven­ture Cap­i­tal, Fund+ on Novem­ber 8, 2017. [more in­for­ma­tion]
De­vel­op­ing dis­ease spe­cif­ic im­mune ther­a­pies to treat se­vere, chron­ic au­to-im­mune, in­flam­ma­to­ry, al­ler­g­ic, in­fec­tious dis­eas­es and tu­mors. [more in­for­ma­tion]
Immune Regulation Ltd
Th­ese ther­a­pies ex­hib­it a short phar­ma­coki­net­ic ac­tiv­i­ty but re­set the im­mune sys­tem from a pro-in­flam­ma­to­ry to a reg­u­la­to­ry state to in­duce long-term dis­ease re­mis­sion in pa­tients with al­ler­g­ic and im­mune me­di­at­ed dis­eas­es, with­out the neg­a­tive ef­fects of chron­ic cur­rent ther­a­pies. [more in­for­ma­tion]
Immunicum AB [IMMU:ST] SKr1,173 MM MCap
Im­mu­nicum is estab­lish­ing a unique im­muno-on­col­o­gy ap­proach through the de­vel­op­ment of al­lo­gene­ic, off-the-shelf cell-based ther­a­pies. Im­mu­nicum's goal is to im­prove sur­vi­val out­comes and qual­i­ty of life by prim­ing the pa­tient’s own im­mune sys­tem to fight can­cer. [more in­for­ma­tion]
InteRNA Technologies
In­teR­NA Tech­nolo­gies pro­vides drug dis­cov­ery and de­vel­op­ment ser­vices. [more in­for­ma­tion]
Kiadis Pharma N.V. [KDS-AMS]
NK-cell plat­form ad­min­is­tered as ad­junct I-O on top of HSCT. Launched FIH POC trial in r/r AML pa­tients (Feb 2020); set to launch ad­di­tio­n­al HSCT trial lat­er in 2020 w/in­ter­im da­ta exp 2021. Pre­sent­ing new da­ta on ex-vi­vo FC21 ex­pand­ed NK-cell ther­a­py in 13 pa­tients at EBMT in 2020. Estab­lished POC in 37 pa­tients to­tal. [more in­for­ma­tion]
Macrophage Pharma
A pri­vate UK based biotech­nol­o­gy com­pany fo­cused on treat­ing hu­man dis­ease by re­pro­gram­ming macrophage func­tion through tran­scrip­tio­n­al re­pro­gram­ming and tar­get­ed drug-de­liv­ery lev­er­ag­ing its pro­pri­e­tary Es­terase Sen­si­tive Mo­tif™ (ESM™) plat­form. [more in­for­ma­tion]
MiNa Therapeutics
De­vel­op­er of ther­a­peu­tic medicines de­signed to har­ness gene ac­ti­va­tion mech­anisms through small ac­ti­vat­ing RNA. The com­pany's tech­nol­o­gy and clin­i­cal know-how trans­form the ther­a­py land­s­cape of can­cer and other se­vere dis­eas­es, en­abling doc­tors and physi­cians to cure can­cer and other se­vere dis­eas­es and de­vel­op new medicines that re­s­tore nor­mal func­tion to pa­tients' cells. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPARg ag­on­ist, MIN-102, in Piv­o­tal Ph 2/3 for X-linked ALD and Ph 2 Frie­drich’s Ataxia; da­ta for both ex­pect­ed by end of 2020. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH (pos­i­tive Ph2b in­ter­im re­sults) and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (Jan 2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]
Nouscom AG
Nous­com is a next-gen­er­a­tion im­munother­a­py com­pany de­vel­op­ing ge­net­ic neoanti­gen vaccines and on­co­lyt­ic virus­es for pre­ven­tion and treat­ment of can­cer. The com­pany has of­fices in Basel and Rome. [more in­for­ma­tion]
NovaGo Therapeutics
No­va­Go Ther­a­peu­tics is a Swiss de­vel­op­ment stage biotech com­pany fo­cused on hu­man anti­body ther­a­peu­tics tar­get­ing blood ves­sel and nerve growth. [more in­for­ma­tion]
Oncimmune [ONC:LN]
Oncim­mune has a di­ver­si­fied and grow­ing rev­enue from its port­fo­lio of di­ag­nos­tic prod­ucts to de­tect ear­ly-stage can­cer and a con­tract dis­cov­ery and de­vel­op­ment ser­vice-based plat­form, de­liv­er­ing ac­tion­able in­sights in­to ther­a­pies to its phar­ma­ceu­ti­cal and biotech part­n­ers. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €702 MM MCap
re­cent in-li­cense from No­var­tis of late stage drug Le­ni­olis­ib for APDS (ul­tra-rare im­mun­od­e­fi­cien­cy con­di­tion), rhC1INH for new larg­er in­di­ca­tions in­clud­ing COVID-19, pre-eclamp­sia, AKI and ad­di­tio­n­al pipe­line prod­uct from tech­nol­o­gy plat­form: re­com­bi­nant al­pha-Glu­cosi­dase for Pompe dis­ease. [more in­for­ma­tion]
He is the former Presi­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va Phar­ma­ceu­ti­cals, where he led the de­vel­op­ment of ~35 new prod­ucts to­wards ap­pro­val in sev­er­al ma­jor mar­kets, pre­dom­i­nant­ly in CNS. Prile­nia is fo­cused on de­vel­op­ing nov­el treat­ments for neu­rode­gen­er­a­tive and neu­rode­vel­op­men­tal di­s­or­ders. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
Po­ten­tial first in class CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors in Ph1b in AML and high-risk MDS, PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni). Da­ta in 2020. Ear­ly stage pipe­line ad­dress­ing emerg­ing solid tu­mor tar­gets. [more in­for­ma­tion]
Scenic Biotech
Al­so known as dis­ease sup­pres­sors, ge­net­ic mod­i­fiers are genes that act to sup­press or com­plete­ly block the ef­fect of a dis­ease-caus­ing mu­tat­ed gene. It is build­ing a pipe­line of dis­ease mod­i­fy­ing ther­a­peu­tics to treat de­v­as­tat­ing dis­eas­es in­clud­ing in­herit­ed rare dis­eas­es and can­cer. [more in­for­ma­tion]
Sensyne Health [SENS] US$1,318 MM MCap
Sen­syne Health op­er­ates as a dig­i­tal health­care com­pany. [more in­for­ma­tion]
Op­er­a­tor of a dis­cov­ery stage biotech com­pany in­tend­ed to rev­o­lu­tion­ize the treat­ment of mi­cro­bial dis­eas­es. The com­pany us­es CRIS­PR tech­nol­o­gy that can sub­vert el­e­ments of the en­doge­nous bac­te­rial CRIS­PR machin­ery to elim­i­nate hazar­dous bac­te­ria in vi­vo, pro­vid­ing the health pro­fes­sio­n­als with medicines that se­lec­tive­ly tar­get and kill bac­te­ria with spe­cif­ic DNA se­quences. [more in­for­ma­tion]
Valbiotis [ALVAL-FR]
At the start of 2020, Val­bi­o­tis signed a glob­al long-term strate­g­ic part­n­er­ship with Nestlé Health Sci­ence for the de­vel­op­ment and com­mer­cial­iza­tion of TO­TUM-63, first ac­tive sub­s­tance in the pipe­line (an in­no­va­tive and pa­tent­ed com­bi­na­tion of 5 plant ex­tracts spe­cif­i­cal­ly de­signed to re­duce the risk of de­vel­op­ing Type 2 Di­a­betes on pre­di­a­bet­ics). [more in­for­ma­tion]
Ver­san­tis is a phase 2a phar­ma­ceu­ti­cal com­pany de­vel­op­ing a new gen­er­a­tion of or­phan medicines to rev­o­lu­tion­ize the care of pa­tients with liv­er dis­eas­es. Ver­san­tis is de­vel­op­ing its lead can­di­date, VS-01, as a first-line med­i­ca­tion for the acute sup­port of cir­rhot­ic and metabolic de­com­pen­sa­tions. VS-01 re­ceived Or­phan Drug desig­na­tion from both FDA and EMA. [more in­for­ma­tion]
Vivoryon [PRBGF] US$119 MM MCap
Vivo­ry­on's pro­grams are based on ded­i­cat­ed re­search, top-lev­el dis­cov­ery and de­ter­mined de­vel­op­ment. The com­pany de­vel­ops first-in-class medicines that tar­get post-trans­la­tio­n­al mod­i­fy­ing en­zymes. The pipe­line con­tains sev­er­al prod­uct can­di­dates across vari­ous stages of de­vel­op­ment, fo­cused on Alzheimer’s Dis­ease and on­col­o­gy. [more in­for­ma­tion]